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I N T R O D U C T I O N
The heteromeric KV7.2/KV7.3 channel is the assembly of 
KV7 channels most commonly found in the central ner-
vous system (Jentsch, 2000; Cooper, 2012). The activity 
of this heteromeric channel gives rise to the K+ current 
that is suppressed by muscarinic signaling and is known 
as the M current (Wang et al., 1998; Jentsch, 2000). M 
currents are critical in controlling excitability in central 
nervous system neurons (Brown and Adams, 1980; Wang 
et al., 1998; Jentsch, 2000; Cooper, 2012; Linley et al., 
2012; Soh et al., 2014; Mastrangelo, 2015; Miceli et al., 
2015a). Indeed, mutations that detrimentally affect the 
function of neuronal KV7 channels cause hyperexcit-
ability syndromes such as benign familial neonatal sei-
zures (Charlier et al., 1998; Singh et al., 1998), early 
onset epileptic encephalopathy (Abidi et al., 2015), and 
peripheral nerve hyperexcitability (Dedek et al., 2001; 
Wuttke et al., 2007). Yet, the molecular basis for the role 
of KV7 channels in the development of these disorders 
remains unclear.
Epilepsy is a family of encephalopathies characterized 
by abnormal synchronous and rhythmic neuronal activ-
ity in the brain that results in seizures. According to the 
Correspondence to Carlos A. Villalba-Galea: 
C a r l o s . V i l l a l b a G a l e a @ v c u h e a l t h . o r g 
Abbreviations used in this paper: AP, action potential; HP, holding 
potential; VSD, voltage-sensing domain.
Centers for Disease Control and Prevention (CDC), 1% 
of children aged 0–17 yr and 1.8% of adults aged 18 yr 
or older have had a diagnosis of epilepsy or seizure dis-
order in 2013. This accounts for over five million peo-
ple in the United States, with an estimate of 56% of 
these identified cases being active epileptic patients 
according to CDC estimates. Epileptic disorders are 
life changing because they can cause learning disabili-
ties and abnormal development in children. Epileptic 
events can also be life threatening because tonic–clonic 
(convulsive) seizures can cause out-of-control muscular 
contractions resulting in injuries.
Epilepsy has a large genetic component (Cooper, 
2012; Mastrangelo, 2015). However, some epileptic dis-
orders, such as benign familial neonatal seizures, are 
monogenic with causative mutations in the KCNQ2 or 
KCNQ3 genes alone (Charlier et al., 1998; Singh et al., 
1998; Wang et al., 1998; Wuttke et al., 2007; Miceli et al., 
2011, 2015a,b; Cooper, 2012; Abidi et al., 2015). In these 
cases, electrical hyperexcitability in neurons is caused 
by ill-performing M currents (Brown and Passmore, 
2009; Maljevic et al., 2010; Cooper, 2012). To compensate 
for this deficiency, pharmacotherapeutic approaches 
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The anticonvulsant Retigabine is a KV7 channel agonist used to treat hyperexcitability disorders in humans. Reti-
gabine shifts the voltage dependence for activation of the heteromeric KV7.2/KV7.3 channel to more negative 
potentials, thus facilitating activation. Although the molecular mechanism underlying Retigabine’s action remains 
unknown, previous studies have identified the pore region of KV7 channels as the drug’s target. This suggested that 
the Retigabine-induced shift in voltage dependence likely derives from the stabilization of the pore domain in an 
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two open states, which we named O1 and O2, with O2 being more stable. The O1 state was reached after short mem-
brane depolarizations, whereas O2 was reached after prolonged depolarization or during steady state at the typical 
neuronal resting potentials. We also found that activation and deactivation seem to follow distinct pathways, sug-
gesting that the KV7.2/KV7.3 channel activity displays hysteresis. As for the action of Retigabine, we discovered that 
this agonist discriminates between open states, preferentially acting on the O2 state and further stabilizing it. Based 
on these findings, we proposed a novel mechanism for the therapeutic effect of Retigabine whereby this drug re-
duces excitability by enhancing the resting potential open state stability of KV7.2/KV7.3 channels. To address this 
hypothesis, we used a model for action potential (AP) in Xenopus laevis oocytes and found that the resting mem-
brane potential became more negative as a function of Retigabine concentration, whereas the threshold potential 
for AP firing remained unaltered.
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230 Resting open state stabilization by Retigabine
Sharp glass electrodes (resistance = 0.2–1 MΩ) were filled with a 
solution containing (in mM) 1,000 KCl, 10 HEPES, and 10 EGTA, 
pH 7.4 (KOH).
Electrophysiological data were filtered at 100 kHz, oversam-
pled at 250 kHz to 2 MHz, and stored for off-line analysis at 5–25 
kHz. For these recordings, a custom LabVIEW-based package was 
used to control a multifunction data acquisition board (USB-6221 
or USB-6251; National Instruments) for voltage command and 
electrical signal acquisition. Data were analyzed using a custom 
Java-based software and Origin2015 (OriginLab).
Oversampling
Oversampling is the process of sampling a signal at a frequency 
much higher than the natural frequency of the system. Electro-
physiological data are typically acquired at frequencies in the kilo-
hertz range. For our study, the acquisition frequency (fa) for 
currents or potential traces was 250 kHz to 2 MHz, after analogue 
filtering at 100 kHz. The sampling frequency for traces was 5–25 
kHz. To decrease high frequency noise, sampled points were cal-
culated by averaging segments of fa/fs points from the acquired 
data. The following example illustrates the process. When acquir-
ing data at 1 MHz, we meant to obtain one acquired point every 
1 µs; when sampling data at 10 kHz, we stored one data point 
every 100 µs. To sample at 10 kHz, we averaged 100-point seg-
ments from the original trace that was acquired at 1 MHz.
“Loose” two-electrode voltage-clamp technique
APs were recorded using a modified two-electrode voltage-clamp 
technique based on the implementation by Shapiro et al. (2012). 
In brief, the command voltage was set to the resting membrane 
potential of the oocytes, and the feedback gain was decreased to 
prevent voltage-clamping. In addition, a 50-MΩ resistor in parallel 
with a 10-MΩ in series with a diode was placed between the cur-
rent-injecting microelectrode and the headstage. With the diode 
anode placed on the headstage side, this arrangement allowed us 
to inject current to depolarize the membrane and trigger APs, but 
not to repolarize it.
Exponential fits and weighted average time constant
As described in previous studies (Lacroix et al., 2011; Labro et al., 
2012; Priest et al., 2013; Villalba-Galea, 2014), deactivating currents 
were fitted to a two-exponential function defined as follows:
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Fittings were done using Origin2015.
ITAIL–V plots fit to Boltzmann equations
To quantify the apparent voltage dependence for activation, ITAIL–V 
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where A1 and A2 are the amplitude associated with each of the 
components, V1 and V2 are the half-activation potential for each 
component, z1 and z2 are the corresponding associated sensing 
charges, k is the Boltzmann constant, and T is absolute temperature. 
have been focused on using drugs that boost the activity 
of KV7 channels (Maljevic et al., 2010). Examples of KV7 
agonists are Retigabine (Main et al., 2000; Rundfeldt 
and Netzer, 2000b), Pyrithione Zinc (Xiong et al., 2007; 
Linley et al., 2012), ICA-27243 (Wickenden et al., 2008), 
and Diclofenac (Peretz et al., 2005). Retigabine is a first-in-
class anticonvulsant that is currently used in the United 
States to treat epileptic disorders in adults (Orhan et al., 
2012). This drug increases activity in Kv7 channels, ex-
cept for KV7.1 (Wickenden et al., 2000, 2008; Peretz 
et al., 2005; Wuttke et al., 2005; Gunthorpe et al., 2012). 
This latter property makes Retigabine an attractive drug 
for the treatment of neurological disorders, as no effect 
on cardiac activity is expected.
Detailed understanding of both the physiological 
behavior and the molecular basis for the activity of neu-
ronal KV7 channels is needed for further refinement 
of the available pharmacotherapy for KV7-related en-
cephalopathies, as well as for the design of new ones. In 
addressing this need, we have discovered that the deac-
tivation kinetics of the heterotetrameric KV7.2/KV7.3 
channel slows down as a function of activity. The changes 
in the deactivation kinetics occurred in at least two stages, 
revealing the existence of two open states, with the sec-
ond open state being more stable than the initial one. 
Further, we found that Retigabine’s action is state depen-
dent, preferentially targeting channels in the more stable 
open state. Furthermore, we found that channels that 
are opened at the typical neuronal resting potential also 
displayed two modes of activity with distinct deactivation 
kinetics and sensitivity to Retigabine. These combined 
observations led us to propose that, although Retigabine 
can change the voltage dependence of activation for KV7 
channels, the stabilization of the channels that are al-
ready opened at neuronal resting potential levels is the 
clinically relevant effect of this anticonvulsant.
M AT E R I A L S  A N D  M E T H O D S
Electrophysiology
Defolliculated Xenopus laevis oocytes were injected with in vitro–
transcribed cRNA encoding for the human KV7.2 and KV7.3 chan-
nels in the vector pTLN. The KV7 constructs were provided by T. 
Jentsch (Leibniz-Institut für Molekulaire Pharmakologie, Berlin, 
Germany). These constructs were linearized with MluI and HpaI, 
respectively (New England Biolabs, Inc.). The linearized DNA was 
transcribed using SP6 RNA polymerase (mMessage mMachine; 
Ambion). Potassium currents were recorded using the Xenopus 
oocyte cut-open voltage-clamp technique using an amplifier (CA-1A; 
Dagan Corporation). The external recording solution contained 
(in mM) 12 KOH, 88 N-methly-d-glucamine, 100 methanesulfonic 
acid, 10 HEPES, and 2 Ca(OH)2. The intracellular solution con-
tained (in mM) 100 KOH, 100 methanesulfonic acid, 10 HEPES, 
and 2 EGTA. Both solutions were titrated to pH 7.4 with methane-
sulfonic acid. Retigabine (Alomone Labs) was dissolved at 50 mM 
in DMSO. The external solution used for control and washouts 
was added with 0.002–0.02% (vol/vol) of DMSO to account for 
the potential effect of the solvent on the activity of the channels. 
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of the channels (Fig. 1 A, arrow), we noticed that the 
deactivation rate of the K+ current decreased as the 
magnitude of the test pulse increased. This feature was 
made evident when normalizing the K+ current traces, 
as we observed that the deactivation was slower when 
occurring from a stronger activating stimulus (Fig. 1 B). 
As previously reported in other studies (Lacroix et al., 
2011; Labro et al., 2012; Priest et al., 2013; Villalba-Galea, 
2014), we quantified the deactivation time constant 
(DEACT) of the K+ current by calculating the weighted 
average time constant from the fitting of a two-exponen-
tial function to the deactivating current. The DEACT  
versus test pulse potential (DEACT–VTEST) plot (Fig. 1 C) 
showed an apparent linear dependence of 1.0 ± 0.2 ms 
(n = 8) in the deactivation time constant per unit of 
millivolt imposed during the activation, indicating that 
the stability of the activated channel increases as a func-
tion of the channel activation.
In terms of stochastic discrete-state modeling of channel 
activity (Colquhoun and Hawkes, 1977), we discerned 
more than one DEACT, which points to the existence of 
more than one open state. Also, the sigmoidal time course 
of the K+ current activation indicates that this process 
The weighted average half-maximum potential (weighted V1/2) 
was calculated using the following equation:
 weighted .V
A V A V
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Fittings were done using Origin2015.
R E S U LT S
Stabilization of the open state of the KV7.2/KV7.3 channel
K+ currents were recorded from Xenopus oocytes co-in-
jected with cRNA encoding for human KV7.2 and KV7.3 
(Fig. 1 A). The activity of the expressed channels was 
assessed by applying test pulses ranging from 120 to 
+60 mV from a holding potential (HP) of 90 mV; K+ 
current amplitude readily increased when applying pulses 
of 50 mV and above. After activation, K+ currents 
were deactivated by applying a pulse to 105 mV (Fig. 1 A, 
arrow). Using this protocol, we recorded K+ currents 
that displayed the typical behavior voltage dependence 
and time-lagged activation of heteromeric KV7.2/KV7.3 
channels (Fig. 1). Focusing our attention on the closing 
Figure 1. K+ deactivation rate decreases as a function of activation. (A) K+ currents recorded from Xenopus oocytes coexpressing human 
KV7.2 and KV7.3 channels using the cut-open voltage-clamp technique. Test pulses ranging from 120 mV to +60 mV were applied from 
an HP of 90 mV. Deactivation of the current was driven at 105 mV (arrow). (B) Normalized deactivating currents from activating 
pulses from 30 to +60 mV. Deactivation slowed down after higher activating potentials. (C) Deactivation time constant (DEACT) versus 
test pulse potential (DEACT–VPULSE) plot. Error bars represent standard deviation. (D) Kinetics scheme describing alternative pathways 
for the deactivation of the heteromeric KV7.2/KV7.3 channel. Voltage-dependent transitions are noted with V.
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of the drug (Fig. 2 A, arrows), indicating that Retiga-
bine was preferentially acting on open channels. Be-
cause KV7.2/KV7.3 possess at least two open states, we 
proceeded to investigate whether Retigabine was able 
to discriminate between them.
Retigabine preferentially binds to the open state O2
The activation of the KV7.2/KV7.3 channels can be in-
creased by applying pulses of higher voltages, longer 
duration, or both. Thus, to further explore how deacti-
vation is affected by Retigabine, we studied how DEACT 
changes as a function of the duration of the depolariza-
tion (DEACT–tPULSE plot). To do so, we recorded the de-
activation of K+ current after activation by 40-mV pulses 
of variable duration (Fig. 3 A) and analyzed how DEACT 
changed as a function of the duration of the activating 
pulse (tPULSE). We observed that deactivation became 
slower as the activating pulse duration increased (Fig. 3 C, 
black squares). We also noticed that DEACT did not 
change for activating pulses shorter than 100 ms (Fig. 3 D, 
black squares), indicating that the stability of the con-
ducting channel increased as a function of activation 
by depolarization lasting >100 ms. In terms of our initial 
model (Fig. 1 D), these observations indicated that 
involves transitions through multiple closed states pre-
ceding channel opening. For this study, we assumed, 
therefore, that the activity of the heteromeric KV7.2/
KV7.3 can be described by a sequential model consisting 
of a series of closed states leading to two open states, O1 
and O2 (Fig. 1 D). In this case, deactivation for the open 
state O2 will be slower, as this process will involve one 
additional transition.
Effect of Retigabine on the deactivation of KV7.2/KV7.3
As before, we recorded K+ currents from oocytes co-in-
jected with KV7.2 and KV7.3 from an HP of 90 mV. We 
applied 1.2-s pulses from 100 to +60 mV followed by a 
pulse to 105 mV to activate and deactivate the chan-
nels, respectively (Fig. 2 A). To assess the effect of Reti-
gabine on the activation of KV7.2/KV7.3 channels, we 
plotted the normalized amplitude of the deactivating 
current (ITAIL) as a function of the activating potential 
(VPULSE). The normalized ITAIL–VPULSE plots showed a 
modest shift toward negative potential in the voltage de-
pendence of channel activation as a function of the con-
centration of Retigabine (Fig. 2 B). In spite of this shift, 
Retigabine seems not to greatly affect activation kinetics 
(Fig. 2 A). In contrast, we observed that deactivation of 
the K+ current was unambiguously slower in the presence 
Figure 2. Effect of Retigabine on the activity of the heteromeric KV7.2/KV7.3 channel. (A) K+ currents recorded in the absence or 
presence of 1–5-µM Retigabine using the same protocol shown in Fig. 1. (B) Average normalized K+ current amplitude measured at the 
beginning of the deactivating currents (ITAIL; arrows in A). Normalized ITAIL versus test pulse potential (ITAIL–VPULSE) plots incrementally 
shift toward negative potentials as the concentration of Retigabine (RTG) was increased. Individual ITAIL–VPULSE plots were fitted to a 
double Boltzmann distribution, and the weighted average half-maximum potential (weighted V1/2) was plotted as a function of the con-
centration of Retigabine (inset). Although the weighted V1/2 values were not statistically different, this parameter changed to more neg-
ative potentials as a function of the concentration of Retigabine in all our recordings. Error bars represent standard deviation. n = 5–8.
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therapeutic effect if this drug is mainly affecting the sec-
ond open state of the KV7.2/KV7.3 channel, which is 
reached after a prolonged, nonphysiological depolar-
ization. In addressing this question, we observed that a 
1.2-s pulse to 60 mV from an HP of 90 mV was able 
to activate 2 ± 2% (n = 10) and 6 ± 2% (n = 10) of the 
maximum KV7.2/KV7.3 conductance observed in our 
recordings in the absence and presence of 10-µM Reti-
gabine, respectively (Fig. 2 B). Because a membrane 
potential of 60 mV is within the range of a typical neu-
ronal resting potential (Bean, 2007), we hypothesized 
that this fraction of channels, which are opened in 
steady state at the resting potential, may be able to reach 
the open state O2. If so, these channels could constitute 
the therapeutically relevant target of Retigabine. To test 
this idea, we compared the deactivation kinetics of K+ 
currents at 90 mV from a pulse-activated open state 
within the first 100 ms of activation, the channels mainly 
populate state O1.
In the presence of 1-µM Retigabine (Fig. 3 B), deacti-
vation became slower than in the absence of the drug 
(Fig. 3 C). Remarkably, Retigabine had no significant 
effect on the deactivation kinetics after activation pulses 
shorter than 500 ms. Therefore, we concluded that Re-
tigabine stabilizes those channels in state O2.
Retigabine stabilizes channels in the open state at the 
resting potential
Thus far, we have shown that Retigabine only targets 
channels that have been activated for a few hundreds 
of milliseconds. However, the duration of a typical neu-
ronal AP is in the order of a few milliseconds (Bean, 
2007). So, we wondered how Retigabine can have any 
Figure 3. Deactivation time constant increase as a function of the duration of the activating pulse. (A and B) K+ currents were activated 
by 40-mV pulses with a duration varying from 10 to 4,175 ms in the absence (A) and presence (B) of 1-µM Retigabine. The duration 
of the pulse increased 1.3-fold for each trace. After activation, the K+ current was deactivated at 90 mV. (C) DEACT–tPULSE plot shows 
that DEACT increased as the activating pulse was longer (black squares). In the presence of Retigabine, DEACT increased further. (D) The 
same plot as in C, but the tPULSE is displayed in a logarithmic scale to highlight the  DEACT–tPULSE relationship for shorter activating pulses 
and showing that DEACT was unaltered by Retigabine for pulses shorter than 500 ms. Error bars represent standard deviation. Control, 
n = 7; Retigabine, n = 6.
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To further investigate the differential effect of Retiga-
bine on channel closing, we carried out a detailed anal-
ysis of the effect of the membrane potential on the 
deactivation of the channel. For this, we recorded K+ 
currents deactivating at different potentials from either 
the pulse-activated open state (Fig. 4 C) or the resting 
potential open state (Fig. 4, D–F). In all cases, we ob-
served that DEACT decreased as the deactivating poten-
tial was more negative (Fig. 4, C–F). Deactivation of the 
K+ currents activated at the resting potential was 10-
fold slower than deactivation of the pulse-activated cur-
rents at all deactivating potentials. As before, in the 
presence of Retigabine, deactivation of the pulse-acti-
vated currents showed no significant changes in DEACT 
with respect to control (Fig. 4 C). In contrast, Retigabine 
significantly increased DEACT for resting potential–acti-
vated currents depending on the deactivating potentials 
and the HP imposed to activate the currents. Particu-
larly, when channels were activated at an HP of 60 mV, 
DEACT increased only when deactivation was driven at 
potentials above 90 mV (Fig. 4 D). Holding the mem-
brane potential at 50 mV (Fig. 4 E) enhanced the 
effect of Retigabine, making DEACT significantly larger 
and from a resting potential open state. To assess the 
first condition, we activated channels by applying a 
100-ms pulse to 40 mV for an HP of 90 mV. To assess 
the second condition, we held the membrane poten-
tial at 50 mV. When driving deactivation at 90 mV, 
we observed that the pulse-activated K+ current deacti-
vated faster (Fig. 4 A, black trace) than the resting po-
tential–activated K+ current (Fig. 4 B, black trace). 
These observations revealed that the open state reached 
by the channels at steady-state resting potential was 
more stable than the open state reached after a 100-ms 
activating pulse. In light of these results, we then won-
dered whether this resting potential open state could 
be further stabilized by Retigabine. To test this, we used 
the same recording protocol, but in the presence of 
1-µM Retigabine. Deactivation from the pulse-activated 
current was not significantly affected by the drug (Fig. 4 A, 
red trace). In contrast, the deactivation rate from the 
resting potential–activated current was unambigu-
ously decreased by the drug (Fig. 4 B, red trace). This 
observation indicated that the stable open state reached 
at the typical neuronal resting potential was sensitive 
to Retigabine.
Figure 4. Deactivation from the depolarized and resting potential open states. (A) Deactivation at 90 mV of the K+ current elicited by 
a 100-ms depolarization to 40 mV in the absence (black trace) and presence of 1-µM Retigabine (red trace). (B) Deactivation at 90 mV 
of the K+ current elicited by holding the membrane potential at 50 mV also in the absence (black trace) and presence of 1-µM Retiga-
bine (red trace). (C–-F) Deactivation time constant (DEACT) versus deactivating potential (DEACT–VDEACT) plot of channels activated by a 
100-ms depolarization to 40 mV (C) or by holding the membrane potential at 60 mV, 50 mV, and 40 mV (D, E, and F, respectively) 
in the absence (black squares) and presence of 1-µM Retigabine (RTG; red circles). Error bars represent standard deviation. t test; n = 
5–8. *, P < 0.05, t test.
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with respect to control (Fig. 5 B), requiring a further 
increase in ITHR, 86%, to reach VTHR (Fig. 5 C). In spite 
of the unambiguous effect of 10-µM Retigabine on 
VREST, Retigabine seemed not to affect VTHR, as this pa-
rameter remained fairly constant in the presence of the 
drug (Fig. 5 B). Because VTHR is the potential at which 
the inwardly rectifying Na+ cancels the outwardly rectify-
ing K+ current, we reasoned that the slow response 
of the heteromeric KV7.2/KV7.3 channel to changes in 
membrane potential results in a negligible increase in 
the contribution of these channels to the K+ conduc-
tance during a single AP. Therefore, the VTHR was mainly 
determined by the activation of NaV1.4 and ShakerIR, 
both of which are not sensitive to Retigabine.
To further evaluate the effect of Retigabine on our 
oocyte AP model, we generated phase plots from rec-
ords of the membrane potential (VM) during an AP. 
Phase plots are built by plotting the first derivative of VM 
with respect to time (dVM/dt) as a function of the VM 
itself (Bean, 2007). Starting at VREST (Fig. 5 D, star), in-
jecting current depolarized the membrane. This was 
seen as a transient positive deflection in the phase plot 
(Fig. 5 D, stimulation [purple arrow]). At the end of the 
current injection, VM was more positive, but dVM/dt 
went back to zero. At this point, if VTHR was reached 
during current injection (Fig. 5, A and D, solid yellow 
arrow), an AP was evoked. As NaV channels were acti-
vated, depolarization appeared as a rapid increase in 
dVM/dt, driving the VM to more positive voltages (Fig. 5 D, 
AP depolarization [green arrow]). Then, the combina-
tion of inactivation of NaV channels and activation of 
KV channels resulted in the decrease of dVM/dt to zero, 
at which the peak voltage of the AP is reached (Fig. 5 D, 
open blue arrow). After the peak, dVM/dt became neg-
ative as the repolarization phase of the AP started. This 
late phase was driven by the activity of KV channels. Re-
markably, we observed that the late phase of the repo-
larization was unaltered by Retigabine (Fig. 5 D, open 
yellow arrow). These observations were consistent with 
the idea that KV7 channel activation was too slow to be 
increased within the time of a single AP. Furthermore, 
Retigabine caused the peak of the AP to be more posi-
tive. We interpreted this to be the result of the recovery 
of NaV channels from steady-state inactivation as a con-
sequence of the VREST hyperpolarization (Fig. 5 C). Based 
on these results, we concluded that the effect of Retiga-
bine on excitability was restricted to the modulation of 
the resting potential open state of the heteromeric 
KV7.2/KV7.3.
D I S C U S S I O N
In agreement with previous studies, our data show that 
Retigabine enhanced the activity of KV7.2/KV7.3 chan-
nels. Previous publications have reported that Retigabine 
boosts channel activity by shifting the voltage dependence 
when deactivating potentials were above 100 mV. Acti-
vation at 40 mV (Fig. 4 F) resulted in a further en-
hancement of the drug’s effect, increasing DEACT at all 
the deactivating potentials that we tested (Fig. 4 F). 
These observations suggested that stabilization of the 
open pore by Retigabine increases the energy barrier 
for deactivation, which has to be overcome by the elec-
trical work the electrical field does on the voltage-sens-
ing domains (VSDs). Therefore, making the membrane 
potential more negative provides more energy for the 
VSD to overcome the Retigabine-induced stabilization 
of the open pore.
Retigabine modulates AP triggering in Xenopus oocytes
Thus far, we have shown that, on one hand, Retigabine 
has no significant effect on deactivation of the hetero-
meric KV7.2/KV7.3 channels that are activated by short 
depolarizing pulses. In contrast, Retigabine stabilizes 
channels that are already opened at the resting poten-
tial. These observations are consonant with the notion 
that Retigabine induces hyperpolarization of the plasma 
membrane (Main et al., 2000; Tatulian et al., 2001; 
Wainger et al., 2014). On the other hand, the activation 
of KV7.2/KV7.3 seems to be too slow to significantly con-
tribute to the increase of the K+ conductance during a 
typical neuronal AP. Therefore, we hypothesized that 
Retigabine would have little or no effect on AP repolar-
ization. To further test this view, we decided to evaluate 
the effect of this anticonvulsant on the generation of 
AP in a system with a defined background of channel 
expression. To do so, we co-injected Xenopus oocytes with 
cRNAs encoding for the sodium-selective, voltage-gated 
channel NaV1.4 ( and  subunits) and the KV chan-
nels ShakerIR, KV7.2, and KV7.3. From such oocytes, we 
were able to evoke AP-like electrical activity using a 
modified (“loose”) two-electrode voltage-clamp tech-
nique (see Materials and methods for details; Shapiro 
et al., 2012). Using this approach, we were able to de-
polarize the membrane to evoke APs while being able 
to poorly voltage-clamp the oocytes (Fig. 5 A). From a 
resting potential (VREST) near 60 mV, a brief (0.25–
0.75 ms) depolarization of the membrane was induced 
by current injection. If the depolarization failed to 
evoke an AP, the membrane potential retuned to its 
resting value within the next 100 ms (Fig. 5 A, gray 
trace). However, if an AP was successfully triggered, 
repolarization was achieved within a few milliseconds 
after the peak of the AP (Fig. 5 A, black trace). Under 
our experimental conditions, the minimum amplitude 
of the current required to evoke an AP (ITHR) ranged 
between 1 and 5 A. In the presence of 1-µM Retiga-
bine (Fig. 5 A, red trace), VREST tended to become more 
negative (Fig. 5 B), requiring an increase of 30% in the 
magnitude of ITHR to reach the threshold potential for 
evoking an AP (VTHR; Fig. 5 C). For 10-µM Retigabine, 
the resting membrane potential became more negative 
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to have a higher impact on the activity of KV7.2/KV7.3 
channels during neuronal activity.
We observed that, along with a slight shift in the volt-
age dependence for activation, Retigabine mainly stabi-
lized KV7.2/KV7.3 channels that were already opened. 
Further, we also observed that these channels deactivate 
in two modalities, revealing the existence of at least two 
types of open states, with deactivation from the second 
(O2) open state being slower (Figs. 3 and 4). Further-
more, we also discovered that Retigabine discriminated 
between these two types of open states, decreasing the 
deactivation rate from the open state O2 (Fig. 1 D). This 
latter finding confirmed the existence of at least two 
open states, as they were distinguished not only by their 
deactivation kinetics, but also by their distinct sensitivities 
for K+ current activation toward more negative values 
(Rundfeldt and Netzer, 2000a,b; Wickenden et al., 2000; 
Schenzer et al., 2005; Wuttke et al., 2005; Gunthorpe 
et al., 2012; Orhan et al., 2012; Kim et al., 2015). Although 
our observations are consonant with these previous stud-
ies (Fig. 2 B), we argue that the effect of Retigabine on 
the deactivation kinetics have a deeper impact on excit-
ability than the change in voltage dependence that fa-
cilitates channel activation. On this topic, we would like 
to point out that the relative slow activation kinetics of 
KV7.2/KV7.3 channels with respect to the lifetime of an 
AP strongly suggests that the number of activated KV7 
channels remains constant during this type of electrical 
event. Hence, slowing down the deactivation of channels 
that are already opened at the resting potential seems 
Figure 5. The resting potential, but not the threshold potential for triggering AP, was affected by Retigabine. (A) APs were recorded 
from Xenopus oocytes coexpressing both the  and  subunits of NaV1.4, ShakerIR, KV7.2, and KV7.3. The APs were recorded using the 
loose two-electrode voltage-clamp technique (see Materials and methods for details) in the absence (black trace) or presence of 1-µM 
(red trace) or 10-µM (green trace) Retigabine. The gray trace shows the response of VM when a subthreshold was applied. The arrow 
indicates the moment at which AP threshold (VTHR) is reached. (B) Effect of Retigabine (RTG) on the resting membrane potential 
(VREST) and AP threshold (VTHR). (C) Minimum current injection needed to evoke an AP (ITHR). The values of ITHR were normalized by 
ITHR in the absence of Retigabine (n = 4). (D) Example of a phase plot calculated from the APs shown on A. VREST was strongly affected 
by Retigabine (blue star), whereas VTHR remained fairly unaltered. Although the depolarization phase was affected by Retigabine (blue 
arrow), the late phase of repolarization (yellow arrow) remained unaltered. Arrows indicate the progress of the AP in time during the 
stimulation phase (purple arrow), depolarization phase (green arrow), and repolarization phase (orange arrow). The open blue arrow 
points at the times when APs reached their maximum voltage. The open yellow arrow points at the late repolarization phase. Error bars 
represent standard deviation. t test; n = 5. *, P < 0.002 with respect to control; **, P < 0.07 with respect to 1-µM Retigabine; ***, P < 0.0025 
with respect to control; #, P < 0.072 with respect to control.
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Nevertheless, as shown in Fig. 4, DEACT at 90 mV can 
reach >2 s. This implies that, assuming a single expo-
nential process for closing, it will take at least 10 s to 
close 99% of the channels. Based on these observations, 
we concluded that short intertrace intervals may lead to 
overestimating the shift in the voltage dependence for 
activation because using short intertrace intervals does 
not allow channels to fully deactivate.
One intriguing observation made in this study is that 
the VTHR for triggering AP remained unaltered by the 
drug. Although we did not directly address this issue, we 
argue that the increased robustness of the K+ conduc-
tance caused by the stabilization of the opened KV7 chan-
nels by Retigabine could be compensated for by the 
increase of the number of available Na+ channels rescued 
from steady-state inactivation. Favoring this idea, we 
found that the amplitude of the AP tended to increase as 
VREST hyperpolarized (Fig. 5 A). Furthermore, we noticed 
that the delay between stimulation and the peak of APs 
shortened in the presence of 10-µM Retigabine, which is 
also consistent with an increase in the number of NaV 
channels driving depolarization (Fig. 5 A). In addition to 
these indirect effects of Retigabine on the availability of 
NaV channels, the closing of KV7.2/KV7.3 channels by hy-
perpolarization may have relieved the channels from the 
action of Retigabine, as this drug only acts on channels 
dwelling in the open state O2. Therefore, in an apparent 
paradox, we propose that Retigabine action constitutes a 
negative feedback loop. As stabilization of the open KV7 
channels drives hyperpolarization of the plasma mem-
brane, channels tend to close. In turn, channels in closed 
states are less sensitive to Retigabine. Therefore, the overall 
effect of the drug decreases.
Another outstanding question is why the effect of Re-
tigabine diminished when deactivation was driven at 
more negative potentials (Fig. 4). On one hand, here, 
we have shown that Retigabine stabilizes those channels 
that are already opened either by a prolonged depolar-
izing pulse or at steady state at the typical neuronal rest-
ing potential. On the other hand, other laboratories 
have shown that the putative binding site for Retigabine 
is located at the intracellular side of the central pore 
domain of KV7 channels (Schenzer et al., 2005; Wuttke 
et al., 2005; Lange et al., 2009; Kim et al., 2015). Thus, 
we concluded that our results could be readily ex-
plained by a kinetic scheme like the one described in 
Fig. 1 D. However, we argue that this scheme may not be 
consonant with the current understanding of the mech-
anism of activity of KV channels. The canonical KV chan-
nel is a tetrameric protein with a central pore domain 
controlled by four VSDs surrounding it (Long et al., 2005, 
2007). Activation of KV channels occurs as membrane 
depolarization drives conformational changes in the 
VSDs (Bezanilla, 2008) that lead to the opening of the 
central pore by a coupling mechanism that is not fully 
understood (Vargas et al., 2012). Likewise, deactivation 
to Retigabine. Combined, these observations cast doubts 
on the notion that the clinically relevant effect of Reti-
gabine is to facilitate channel activation. Instead, our 
findings indicate that Retigabine stabilizes those chan-
nels that have been already activated.
Inquiring about the mechanism of KV7.2/KV7.3 chan-
nel activity, we wondered whether the two open states or 
modes were the consequence of the channels being 
formed by two different types of subunits, KV7.2 and 
KV7.3. This idea requires that the stabilization of the 
conductance is caused by differential contributions of 
both subunit types to the conductive states of the chan-
nels. If so, this would imply that Retigabine is acting 
only on one type of subunit, as only the deactivation of 
the more stable open state is affected by the drug. How-
ever, both KV7.2 and KV7.3 are sensitive to Retigabine 
(Main et al., 2000; Rundfeldt and Netzer, 2000b; Wuttke 
et al., 2005, 2008; Kim et al., 2015). Thus, this later pos-
sibility is likely not probable. Therefore, we argue that 
the two different open states are not caused by the het-
eromeric nature of the channel.
The lack of effect of Retigabine on the stabilization of 
O1 indicates that these modes likely represent distinct 
sets of conformations of the activated channel. Thus, 
the emerging question is, which of the available KV7 
channel models corresponds to the state O2? Address-
ing this question highlights that a detailed understand-
ing of the atomic interactions underlying the effect of 
anticonvulsants is needed to expedite the development 
of new drugs. A few residues in the intracellular side of 
the pore have been identified as critical for the inter-
action of KV7 channels and Retigabine. Among them, a 
Tryptophan on the channel’s fifth transmembrane (S5) 
segments, namely W236 in KV7.2 (Schenzer et al., 2005; 
Wuttke et al., 2005) and the corresponding W265 in 
KV7.3 (Schenzer et al., 2005; Kim et al., 2015), is a key 
player for the atomic interaction underlying the action 
of Retigabine, whereby removing a single hydrogen 
bond impairs drug action (Kim et al., 2015). Thus, the 
structural differences associated with the open states O1 
and O2 may depend on subtle rearrangements within 
the pore domain.
One outstanding question is why the changes in volt-
age dependence of activity that we observed were much 
lower than reported by other laboratories. We assessed 
voltage dependence of the KV7.2/KV7.3 channel using a 
pulse protocol like the one shown in Fig. 2 A. During 
the initial stages of this project, we observed that Reti-
gabine changed the voltage dependence for current 
activation over 20 mV. However, we also noticed that 
increasing the duration of the period of time between 
each trace (intertrace intervals) from 1–2 s to 10–25 s 
decreased the shift in voltage dependence. So, we mod-
ified our protocols and, regretfully, did not systematically 
follow up on this matter at that time; we are currently 
addressing this issue, as further experiments are needed. 
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open state (O2) is reached from O1. In the presence of 
Retigabine, the stability of O2 is enhanced. According 
to the scheme in Fig. 1 D, deactivation only occurs from 
O1, which implies that channels need to be relieved from 
the action of the drug before closing. Although this is a 
possible scenario, in terms of the current understand-
ing of structure-function of channels, there is no reason 
to believe that the VSD will not deactivate from state O2. 
Based on this idea, we argue that the initial scheme de-
picted in Fig. 1 D seems to be insufficient to describe 
our findings. To address this issue, we have modified 
our original kinetic scheme to explicitly define the VSDs 
and pore as intrinsically independent modules that are 
coupled (Fig. 6). For simplicity, we represented the acti-
vation of four VSDs to occur in a single step instead of 
the explicit 16 states emerging from all the possible 
combinations of activated and deactivated VSDs and 
pore domain. Also, another simplification implemented 
is that we did not make any explicit distinction between 
KV7.2 and KV7.3 subunits. The purpose of this new scheme 
(Fig. 6) is to illustrate a basic framework that allows us 
to describe our findings in terms of what we know on 
the dynamics of VSD proteins. According to the new 
scheme, hyperpolarization of the membrane drives the 
four VSDs into their deactivated conformation (VSDD), 
which in turn keeps the pore closed (PC0; Fig. 6, state 
VSDD/PC0). As the membrane potential becomes more 
positive (e.g., at the membrane resting potential), VSD 
sojourns between the VSDD and the activated (VSDA) 
state, allowing the pore to also sojourn between the 
nonconductive (PC1) and the conductive (PO1) states 
(Fig. 6). If the membrane is immediately hyperpolar-
ized, VSD deactivates, driving the pore domain back to 
state PC0. In contrast, holding the membrane at the rest-
ing potential will allow the pore to eventually change 
conformation into a second set of open (PO2) and closed 
(PC2) states. From these new states, deactivation is slower, 
as the pore has stabilized. In addition, the channels be-
come Retigabine sensitive, so that in the presence of 
this drug, the pore is further stabilized and deactivation 
becomes slower.
Open pore stabilization provides a straightforward 
mechanism for hysteresis in KV channels. However, the 
charge movement of an isolated VSD can also show 
hysteresis through an intrinsic process known as VSD 
relaxation (Villalba-Galea et al., 2008, 2009). After re-
laxation, the voltage dependence for charge movement 
(sensing/gating currents) can shift to more negative 
potentials as well as to become slower. This implies that 
hysteresis in KV7 channels could also originate from 
VSD relaxation (Lacroix et al., 2011; Labro et al., 2012). 
Our observations, alas, do not allow us to evaluate this 
possibility, as we have not been able to record gating 
currents from KV7.2/KV7.3.
In spite of the findings reported here, the overall 
impact that hysteresis can have on electrical signaling 
of KV channels is caused by the repolarization of the 
plasma membrane that drives VSDs toward their initial 
resting conformation, which, in turn, closes the central 
pore. As already mentioned, one interpretation for these 
results is that, at more negative potential, the increased 
driving force for the movement of the VSD provides 
enough energy to overcome the effect of Retigabine.
Another aspect to be considered is that the sequence 
of events inherent to the closing of channels is not ex-
actly the reverse sequence of events observed during 
the opening; changes in the conductive status is always 
initiated by electrically driven changes in the VSD. In 
this view, activation and deactivation follow distinct 
pathways that may display distinct voltage sensitivities. 
Indeed, a commonly overlooked feature of KV channels 
and other VSD proteins is that their activity displays hys-
teresis (Bezanilla et al., 1982; Shirokov et al., 1992; Olcese 
et al., 1997; Pennefather et al., 1998; Piper et al., 2003; 
Kuzmenkin et al., 2004; Männikkö et al., 2005; Villalba- 
Galea et al., 2008; Akemann et al., 2009; Xiao et al., 2010; 
Lacroix et al., 2011; Benndorf et al., 2012; Labro et al., 
2012; Priest et al., 2013; Villalba-Galea, 2014; Li et al., 
2015). Hysteresis is a property of many physical and 
chemical systems whereby their response to a stimulus 
depends on whether the magnitude of the stimulus is 
increasing or decreasing. In KV channels, hysteresis is 
manifested as a shift in the voltage dependence of their 
activity, a decrease in the deactivation rate, or both (Olcese 
et al., 1997; Pennefather et al., 1998; Piper et al., 2003; 
Lacroix et al., 2011; Labro et al., 2012; Priest et al., 2013). 
In the case of ShakerIR and KV1.2, the relationship be-
tween DEACT and duration of the activation pulse (DE-
ACT–-tPULSE plot) increases in three stages: the first one in 
which DEACT is small and remains constant, a second 
stage in which DEACT increases, and a third stage in 
which DEACT reaches a plateau (Labro et al., 2012). The 
first stage is associated with stabilization of the open 
pore, and the last stage is the result of VSD relaxation. 
This latter process is a hysteretic mechanism that is in-
trinsic of the VSD (Villalba-Galea et al., 2008, 2009, 
2013; Akemann et al., 2009; Lacroix et al., 2011; Villalba- 
Galea, 2012, 2014). Here, we show that the DEACT–tPULSE 
plot for KV7.2/KV7.3 also displays three stages, with the 
third one, however, not reaching a plateau within the 
time frame used in these studies. This observation sug-
gests that the deactivation for state O2 follows a distinct 
voltage-dependent pathway, implying that the activity of 
KV7.2/KV7.3 is hysteretic. In this view, stabilizing the 
pore domain in an open conformation can cause a shift 
in voltage dependence, as channel closing will require 
more energy.
According to the sequential model in Fig. 1 D, depo-
larization drives the VSDs from their deactivated con-
formations to the activated ones. In doing so, the energy 
gained by this electrical work drives the opening of the 
pore to the first open state (O1). Eventually, the second 
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On a final note, knowing that the activation of KV7.2/
KV7.3 takes several tens of milliseconds to occur (Fig. 1 A), 
whereas a typical neuronal AP lasts less than a couple of 
milliseconds (Fig. 5; Bean, 2007), highlights the apparent 
disconnect between the kinetics of both processes. This 
upholds the idea that, during the lifetime of an AP, the 
number of activated KV7.2/KV7.3 channels likely remains 
constant. In our view, this is consistent with the notion 
that neuronal KV7 channels function as regulators of excit-
ability by contributing the control of the resting potential 
(Jentsch, 2000; Peters et al., 2005; Miceli et al., 2008; 
Cooper, 2012). Thus, our observations indicate that the 
voltage-dependent activation of KV7.2/KV7.3 channels 
may constitute a mechanism that is physiologically rele-
vant only at transmembrane voltages near the resting 
potential. Therefore, the use of activation by depolar-
ization to experimentally evaluate the effect of drugs or 
mutations on these channels may not be suitable.
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and its biological role remain elusive. Here, for the first 
time, we provide an example of hysteresis in the activity 
of a KV channel that directly affects the channel’s phar-
macology under physiological conditions. In line with 
recent findings on the action of Retigabine on the iso-
lated pore of KV7 channels (Syeda et al., 2015), our ob-
servations clearly show that the stabilized open state of 
the KV7.2/KV7.3 channel is the target for the action 
of the anticonvulsant Retigabine. These findings have 
several implications. First, using the effect on the acti-
vation of the KV7 channels is an important but not suffi-
cient parameter when evaluating new drugs targeting 
the activity of these channels. Second, the observation of 
a hysteretic behavior in the activity of KV7 channels 
implies the existence of two or more distinct sets of 
open states. These sets of states are likely associated with 
also structurally distinct sets of conformations. Our re-
sults showed that Retigabine can differentially affect 
the stability of these states, confirming that the channel 
adopts a different set of conformations that can be 
pharmacologically discriminated. It remains to be estab-
lished, however, whether the stabilization of the second 
open state (O2) is driven by conformational changes in 
the pore, VSD relaxation, or both. For this, future stud-
ies will need to directly study the dynamics of the VSD 
and determine whether the VSD of KV7 channels re-
laxes. On this issue, no study showing gating currents 
from these channels has been reported to our knowl-
edge. Recording gating currents from both KV7.2 and 
KV7.3 has proven technically challenging, as we also 
failed to record gating currents during the present 
study. At this point, we can conclude that, although it 
seems that Retigabine is acting on the pore domain, we 
cannot rule out the possibility that VSD relaxation is in-
volved in the stabilization of the open state.
Figure 6. Proposed kinetic scheme for the activ-
ity of KV7.2/KV7.3 and the effect of Retigabine. 
The scheme contains five global states, which are 
different with respect to each other depending 
on the activation status of the VSD and the pore 
domain (P). In the scheme, VSD represents the 
four voltage sensors of the channel. At negative 
potentials, the VSDs are in the deactivated state 
(VSDD) and the pore is, therefore, closed (PC0). 
Upon depolarization, the VSDs are activated 
(VSDA), allowing the pore to sojourn between a 
conductive and a nonconductive state (PO1 and 
PC1, respectively). Holding the membrane depo-
larized potentials keeps the VSDs in the VSDA 
state while allowing a second transition in the 
pore. As a result, the pore sojourns between a 
second pair of conductive and nonconductive 
states (PO2 and PC2, respectively) and the channel 
becomes Retigabine sensitive. Deactivation from 
these states is slower than from the pair PC1–PO1. 
Retigabine further decreases the rate of deactiva-
tion from the pair PC2–PO2 while leaving deactiva-
tion unaffected from the other pair.
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